Browse > Article
http://dx.doi.org/10.3340/jkns.2011.50.5.426

Chemotherapy for Malignant Gliomas Based on Histoculture Drug Response Assay : A Pilot Study  

Gwak, Ho-Shin (Department of Neuro-Oncology Clinic, National Cancer Center)
Park, Hyeon-Jin (Center for Pediatric Oncology, National Cancer Center)
Yoo, Heon (Department of Neuro-Oncology Clinic, National Cancer Center)
Youn, Sang-Min (Department of Neurosurgery, Korea Institute of Radiological and Medical Science)
Rhee, Chang-Hun (Department of Neurosurgery, Korea Institute of Radiological and Medical Science)
Lee, Seung-Hoon (Department of Neuro-Oncology Clinic, National Cancer Center)
Publication Information
Journal of Korean Neurosurgical Society / v.50, no.5, 2011 , pp. 426-433 More about this Journal
Abstract
Objective : The Histoculture Drug Response Assay (HDRA), which measures chemosensitivity using minced tumor tissue on drug-soaked gelfoam, has been expected to overcome the limitations of in vitro chemosensitivity test in part. We analyzed interim results of HDRA in malignant gliomas to see if the test can deserve further clinical trials. Methods : Thirty-three patients with malignant gliomas were operated and their tumor samples were examined for the chemosensitivity to 10 chosen drugs by HDRA. The most sensitive chemotherapy regimen among those pre-established was chosen based on the number of sensitive drugs or total inhibition rate (IR) of the regimen. The response was evaluated by 3 month magnetic resonance image. Results : Among 13 patients who underwent total resection of the tumor, 12 showed no evidence of disease and one patient revealed progression. The response rate in 20 patients with residual tumors was 55% (3 complete and 8 partial responses). HDRA sensitivity at the cut-off value of more than one sensitive drug in the applied regimen showed a sensitivity of 100%, specificity of 60% and predictability of 70%. Another cut-off value of >80% of total IR revealed a sensitivity of 100%, specificity of 69%, and predictability of 80%. For 12 newly diagnosed glioblastoma patients, median progression-free survival of the HDRA sensitive group was 21 months, while that of the non-sensitive group was 6 months ($p$=0.07). Conclusion : HDRA for malignant glioma was inferred as a feasible method to predict the chemotherapy response. We are encouraged to launch phase 2 clinical trial with chemosensitivity on HDRA.
Keywords
Chemotherapy; Drug sensitivity tests; Malignant glioma;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Boiardi A, Eoli M, Salmaggi A, Pollo B, Milanesi I, Broggi G, et al. : Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. J Neurooncol 49 : 71-75, 2000   DOI   ScienceOn
2 Choi IS, Lee SH, Kim TY, Bang JS, Paek SH, Kim S, et al. : Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 60 : 171-176, 2002   DOI   ScienceOn
3 Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP : Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 : 2585-2597, 1993   DOI   ScienceOn
4 Furukawa T, Kubota T, Hoffman RM : Clinical applications of the histoculture drug response assay. Clin Cancer Res 1 : 305-311, 1995
5 Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, et al. : High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51 : 489-498, 1992   DOI
6 Gilbert M, O'Neill A, Grossman S, Grunnet M, Mehta M, Jubelirer S, et al. : A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme : an Eastern Cooperative Oncology Group study (E2393). J Neurooncol 47 : 145-152, 2000   DOI   ScienceOn
7 Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, et al. : Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme : Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21 : 1485-1491, 2003   DOI   ScienceOn
8 Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltzman M, Yue N, et al. : Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15 : 2596-2603, 1997   DOI
9 Guo HY, Colangelo D, Li L, Connors KM, Kubota T, Hoffman RM : In vitro histoculture of human tumors with fluorescent dye end-points measured by confocal microscopy : high correlation of in vitro and in vivo chemosensitivity. Anticancer Res 12 : 1055-1061, 1992
10 Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. : Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay : clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55 : 5276-5282, 1995
11 Bogdahn U : Chemosensitivity of malignant human brain tumors. Preliminary results. J Neurooncol 1 : 149-166, 1983
12 Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Hata K, et al. : Data acquisition for the histoculture drug response assay in lung cancer. J Thorac Cardiovasc Surg 133 : 303-308, 2007   DOI   ScienceOn
13 Wen PY, Kesari S : Malignant gliomas in adults. N Engl J Med 359 : 492-507, 2008   DOI   ScienceOn
14 Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. : Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 28 : 1963-1972, 2010   DOI   ScienceOn
15 Yamauchi M, Satta T, Ito A, Kondo T, Takagi H : A feasibility study of the SDI test for the evaluation of gastrointestinal cancer sensitivity to anticancer drugs. J Surg Oncol 47 : 253-260, 1991   DOI   ScienceOn
16 Skalski V, Rivas J, Panasci L, McQuillan A, Feindel W : The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines : analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chemother Pharmacol 22 : 137-140, 1988
17 Yung WK : In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg Rev 12 : 197-203, 1989   DOI   ScienceOn
18 Yung WK, Janus TJ, Maor M, Feun LG : Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neurooncol 12 : 131-135, 1992
19 Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, et al. : Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24 : 437-442, 2002   DOI   ScienceOn
20 Stewart LA : Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 : 1011-1018, 2002   DOI   ScienceOn
21 Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM : In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci U S A 84 : 5029-5033, 1987   DOI   ScienceOn
22 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005   DOI   ScienceOn
23 Suda S, Akiyama S, Sekiguchi H, Kasai Y, Ito K, Nakao A : Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg Today 32 : 477-481, 2002   DOI   ScienceOn
24 Vescio RA, Connors KM, Kubota T, Hoffman RM : Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. Proc Natl Acad Sci U S A 88 : 5163-5166, 1991   DOI   ScienceOn
25 Weaver JR, Wientjes MG, Au JL : Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. Cancer Chemother Pharmacol 44 : 335-342, 1999   DOI   ScienceOn
26 Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, et al. : Chemosensitivity testing of ovarian cancer using the histoculture drug response assay : sensitivity to cisplatin and clinical response. Int J Gynecol Cancer 15 : 445-452, 2005   DOI   ScienceOn
27 Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, et al. : Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20 : 2049-2054, 2000
28 Qin D, Ou G, Mo H, Song Y, Kang G, Hu Y, et al. : Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier : clinical results. Int J Radiat Oncol Biol Phys 51 : 959-962, 2001   DOI   ScienceOn
29 Pathak KA, Juvekar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, et al. : In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer 44 : 142-146, 2007   DOI   ScienceOn
30 Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. : High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma : European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 : 4483-4488, 2003   DOI   ScienceOn
31 Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, et al. : Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide : a phase II study. Eur J Cancer 32A : 2229-2235, 1996
32 Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR : American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22 : 3631-3638, 2004   DOI   ScienceOn
33 Lassen U, Kristjansen PE, Wagner A, Kosteljanetz M, Poulsen HS : Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neurooncol 43 : 161-166, 1999   DOI   ScienceOn
34 Kochii M, Kitamura I, Goto T, Nishi T, Takeshima H, Saito Y, et al. : Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma. J Neurooncol 49 : 63-70, 2000   DOI   ScienceOn
35 Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, et al. : In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol 11 : 449-453, 2006   DOI   ScienceOn
36 Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, et al. : Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1 : 1537-1543, 1995
37 Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, et al. : Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64 : 237-244, 1980
38 Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response criteria for phase III studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-1280, 1990   DOI
39 Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S, et al. : In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res 21 : 4147-4151, 2001
40 Mosmann T : Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assays. J Immunol Methods 65 : 55-63, 1983   DOI
41 Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH : ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas : phase II study. J Neurooncol 75 : 173-180, 2005   DOI   ScienceOn
42 Hochberg FH, Parker LM, Takvorian T, Canellos GP, Zervas NT : High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 54 : 455-460, 1981   DOI
43 Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, et al. : Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43 : 749-756, 2007   DOI   ScienceOn
44 Haselsberger K, Peterson DC, Thomas DG, Darling JL : Assay of anticancer drugs in tissue culture : comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma. Anticancer Drugs 7 : 331-338, 1996   DOI   ScienceOn
45 Hirano Y, Ushiyama T, Suzuki K, Fujita K : Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers : wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res 27 : 483-488, 1999   DOI   ScienceOn
46 Iwadate Y, Fujimoto S, Namba H, Yamaura A : Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing. Br J Cancer 89 : 1896-1900, 2003   DOI   ScienceOn
47 Kanasugi M, Aoki D, Suzuki N, Susumu N, Nakata S, Horiuchi M, et al. : Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer. Int J Gynecol Cancer 16 : 409-415, 2006   DOI
48 Kim IK, Yoo H, Shin SH, Youn SM, Rhee CH, Lee SH, et al. : Histoculture drug response assay for brain tumors : a preliminary study for evaluability and compatibility. J Korean Brain Tumor Soc 9 : 67-73, 2010
49 Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, et al. : Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 24 : 209-218, 2009   DOI   ScienceOn